Plain-English translation of NCT06793917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called , when combined with chemotherapy, can help treat advanced stomach cancer better than chemotherapy by itself. is an immunotherapy—a type of drug that helps your immune system recognize and fight cancer cells. The trial will compare this new combination approach to standard chemotherapy to see which works better.
Advanced stomach cancer is very difficult to treat, and current chemotherapy-only approaches don't work well enough for all patients. This medication might help by training the immune system to attack cancer more effectively alongside chemotherapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new immune therapy combined with one type of chemotherapy, or the new immune therapy combined with a different type of chemotherapy. You will visit the research center regularly for treatment infusions and blood tests to monitor how well the treatment is working and how your body is handling it. The trial will track your health and any side effects over time as the study team compares how well each treatment combination works.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China